Upstream Bio (UPB) data was positive but not 'home run', says TD Cowen
Tweet Send to a Friend
TD Cowen analyst Yaron Werber reiterated a Buy rating on Upstream Bio (NASDAQ: UPB).Werber wrote, "Today's Ph2 VALIANT asthma data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
